• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer
  • VIEWS 56
  • PDF 16

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v23.2.1

Year: 2024, Volume: 23, Issue: 2, Pages: 124-128

Original Article

Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer

Hosnie Hoseini1,∗, Azade Sarani2

1Department of Laboratory Sciences, Zahedan Branch, Islamic Azad University, Zahedan, Iran
2Department of Midwifery, Faculty of Medical Science, Zahedan Branch, Islamic Azad University, Zahedan, Iran


*Corresponding author:
[email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Pancreatic cancer (PC) is one of the most lethal tumor malignancies, which has a poor prognosis and can be the cause of death despite tumor removal. New molecular investigations for therapeutic purposes have shown the expression of HER3 in pancreatic adenocarcinoma. Family receptors HER3 play an effective role in malignancies such as lung and colon cancer. The aim of this study is to investigate the expression of HER3 in pancreatic cancer samples and the relationship between the expression of the receptor HER3 and the clinical complications of patients. Samples were taken from 75 patients with pancreatic cancer and subjected to immunohistochemical staining to evaluate the expression. Based on the intensity of staining, scores were assigned to each sample for HER3 receptor. Scores of +2 or +3 were defined as positive staining. The obtained data were analyzed using SPSS 16 software and Chi-square tests. P<0.05 was considered statistically significant. The results showed the expression of HER3 in normal pancreatic tissue. The expression decreased from the early to late stage (p=0.05). Multivariate survival analysis showed that only stage had independent prognostic value (p=0.015). HER3 expressed in normal pancreatic tissue, but the expression is lost in pancreatic cancer. According to the study, it seems that targeted treatment in pancreatic cancer has no relationship with expression.

Keywords

EGFR, HER3, Pancreatic adenocarcinoma, Prognosis

References

  2. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Molecular Cancer Therapeutics. 2012;11(3):582–593. Available from: https://doi.org/10.1158/1535-7163.mct-11-0820
  3. Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014;5(23):11847–11856. Available from: https://doi.org/10.18632/oncotarget.2663
  4. Lau C, Killian KJ, Samuels Y, Rudloff U. ERBB4 mutation analysis: emerging molecular target for melanoma treatment. Methods in Molecular Biology . 2014;1102:461–480. Available from: https://doi.org/10.1007%2F978-1-62703-727-3_24
  5. Perini MV, Montagnini AL, Coudry R, Patzina R, Penteado S, Abdo EE, et al. Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis. ANZ Journal of Surgery. 2015;85(3):174–178. Available from: https://doi.org/10.1111/ans.12399
  6. El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, et al. The current state of molecular testing in the treatment of patients with solid tumors. CA: A Cancer Journal for Clinicians. 2019;69(4):305–343. Available from: https://doi.org/10.3322/caac.21560
  7. Smith SM, Wachter K, Burris HA, Schilsky RL, George DJ, Peterson DE, et al. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. Journal of Clinical Oncology. 2021;39(10):1165–1184. Available from: https://doi.org/10.1200/jco.20.03420
  8. Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel). 2020;13(9):1–31. Available from: https://doi.org/10.3390/ph13090245
  9. Chalouni C, Doll S. Fate of antibody-drug conjugates in cancer cells. Journal of Experimental & Clinical Cancer Research. 2018;37(1):1–12. Available from: https://doi.org/10.1186/s13046-017-0667-1
  10. Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, et al. A novel HER3 targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clinical Cancer Research. 2019;25(23):7151–7161. Available from: https://doi.org/10.1158/1078-0432.ccr-19-1745
  12. Qi Z, Wang L, Desai K, Cogswell J, Stern M, Lawson B, et al. Reliable gene expression profiling from small and hematoxylin and eosin-stained clinical formalin-fixed, paraffin-embedded specimens using the HTG EdgeSeq platform. Journal of Molecular Diagnostics. 2019;21(5):796–807. Available from: https://doi.org/10.1016/j.jmoldx.2019.04.011
  13. Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology. 2019;37(14):1169–1178. Available from: https://doi.org/10.1200/JCO.18.00925
  14. Sunakawa Y, Wang E, Roberts C, Yang D, Liu Q, Thompsom D, et al. Association of gene signature to identify molecular subtypes with clinical outcomes of 1st-line cetuximab (cet) treatment for metastatic colorectal cancer (mCRC) Journal of Clinical Oncology. 2016;34(15_suppl):3592. Available from: https://doi.org/10.1200/JCO.2016.34.15_suppl.3592
  15. Koshkin VS, Dhawan A, Hu M, Reynolds J, Elson P, McKenney J, et al. Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC) Journal of Clinical Oncology. 2018;36(15_suppl):4546. Available from: https://doi.org/10.1200/JCO.2018.36.15_suppl.4546
  16. Kobel M, Rahimi K, Rambau PF, Naugler C, Page CL, Meunier L, et al. An immunohistochemical algorithm for ovarian carcinoma typing. International Journal of Gynecological Pathology. 2016;35(5):430–441. Available from: https://doi.org/10.1097/pgp.0000000000000274
  17. Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):1–22. Available from: https://doi.org/10.1371/journal.pone.0157368
  18. QL, Zhang R, Yan H, Zhao P, LW, Wang H, et al. Prognostic significance of HER3 in patients with malignant solid tumors. Oncotarget. 2017;8(40):67140–67151. Available from: https://doi.org/10.18632%2Foncotarget.18007
  19. Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, et al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Scientific reports . 2019;9(1):1–9. Available from: https://doi.org/10.1038/s41598-019-43678-6
  20. Haikala HM, Lopez T, Köhler J, Eser PO, Xu M, Zeng Q, et al. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd. Cancer Research. 2022;82(1):130–141. Available from: https://dx.doi.org/10.1158/0008-5472.can-21-2426
  22. Yu HA, Baik C, Gold K, Hayashi H, Johnson ML, Koczywas M, et al. Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients with EGFR-mutated NSCLC. Annals of Oncology. 2020;31(S4):S1189–S1190. Available from: https://doi.org/10.1016/j.annonc.2020.08.2295
  23. Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2017;1868(1):69–92. Available from: https://dx.doi.org/10.1016/j.bbcan.2017.02.003
  24. Capone E, Lamolinara A, D'Agostino D, Rossi C, Laurenzi VD, Iezzi M, et al. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. Journal of Controlled Release. 2018;277:48–56. Available from: https://dx.doi.org/10.1016/j.jconrel.2018.03.016
  25. Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, et al. An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. Oncogene. 2019;38(9):1398–1409. Available from: https://dx.doi.org/10.1038/s41388-018-0517-4

Copyright

© 2024 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 16 September 2024

Year: 2024, Volume: 23, Issue: 2


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.